ASB20123 | GMP Supplier & Manufacturer for Research Use

描述

1. Product Description 

ASB20123 is a chimeric peptide combining C-type natriuretic peptide (CNP) and ghrelin sequences, engineered to stimulate longitudinal bone growth through synergistic effects on growth plate chondrocytes and bone remodeling pathways. Growth plate research is critical for understanding disorders such as achondroplasia, dwarfism, and other skeletal dysplasias.

Background

CNP plays a vital role in endochondral ossification, regulating chondrocyte proliferation and differentiation. Ghrelin, a growth hormone secretagogue, stimulates GH release and promotes anabolic effects on skeletal tissue. ASB20123 integrates these two mechanisms, creating a potent bone growth-promoting peptide for preclinical research applications.

Scientific Relevance

• Bone Growth Research: Enables studies on chondrocyte proliferation, differentiation, and bone elongation.

• Endocrine Pathway Analysis: Facilitates investigation of CNP/NPR-B signaling and ghrelin-GH axis interaction.

• Therapeutic Development: Provides insights for growth disorder therapeutics, including pharmacological interventions in dwarfism.

• Comparative Peptide Studies: Useful for testing different analogues and dosing strategies for skeletal growth optimization.

Comparison with Other Peptides

• CNP analogues – Primarily target growth plate chondrocytes.

• Ghrelin analogues – Mainly enhance GH secretion.

• ASB20123 – Combines both CNP and ghrelin functions, offering additive or synergistic effects on bone growth.

Advantages in Research

• Dual mechanism ensures enhanced bone growth stimulation.

• GMP-grade production guarantees reproducible results in laboratory experiments.

• Compatible with in vitro chondrocyte cultures, ex vivo bone models, and in vivo animal studies.

• Stable lyophilized form allows long-term storage and transport.

2. Product Specifications 

3. Mechanism of Action & Research Applications 

Mechanism of Action

ASB20123 functions via dual signaling pathways:

1. CNP Component

   • Activates natriuretic peptide receptor-B (NPR-B) on chondrocytes.

   • Increases intracellular cGMP levels, promoting chondrocyte proliferation and differentiation.

   • Enhances endochondral ossification, accelerating longitudinal bone growth.

2. Ghrelin Component

   • Stimulates growth hormone (GH) release via hypothalamic-pituitary axis.

   • Induces IGF-1 secretion, which synergistically supports bone formation.

Research Applications

1. Growth Disorder Models

   • Investigating therapies for achondroplasia, dwarfism, and other skeletal dysplasias.

2. Endocrinology Studies

   • Exploring CNP/NPR-B signaling, ghrelin-GH axis interactions, and growth factor regulation.

3. In Vitro Chondrocyte Studies

   • Assessing cell proliferation, differentiation, and extracellular matrix deposition in cultured growth plate cells.

4. Ex Vivo Bone Culture

   • Monitoring epiphyseal growth plate elongation and bone matrix formation.

5. Animal Models

   • Testing pharmacological efficacy in rodent or larger animal models of growth deficiency.

6. Translational Research

   • Informing development of novel therapeutics for pediatric growth disorders.

Advantages for Research

• Synergistic effect improves bone growth stimulation over single-component peptides.

• GMP-grade reproducibility ensures consistency across preclinical studies.

• Versatility for multi-modal applications in chondrocyte biology, endocrinology, and skeletal research.

  

4. Side Effects (Research Reference) 

In preclinical studies, ASB20123 demonstrates:

• Dose-Dependent Growth Stimulation: Excessive dosing may lead to overgrowth in animal models.

• Metabolic Effects: Ghrelin component may influence appetite and glucose metabolism.

• Skeletal Abnormalities: High doses over prolonged periods may alter bone geometry.

• Species-Specific Responses: Rodent vs. larger animal responses may vary.

• Stability Considerations: Proper storage essential to maintain peptide activity.

These observations are for laboratory research reference. ASB20123 is not approved for human or veterinary use.

5. Disclaimer

For laboratory research use only. Not for human or veterinary use.

6. Keywords

• ASB20123

• ASB20123 peptide

• CNP/Ghrelin chimeric peptide

• Bone growth research peptide

• Growth disorder research peptide

• Dwarfism research peptide

• GMP supplier ASB20123

• Skeletal development peptide

• Growth plate research peptide

• Laboratory use bone growth peptide